Terapia Intensiva
Estudo randomizado | Tratamento precoce da COVID-19 com anakinra orientado pelos níveis plasmáticos de receptor de plasminogênio de uroquinase solúvel.
6 Set, 2021 | 16:34h
Comentário no Twitter
The SAVE-MORE phase 3 study demonstrates the efficacy of anakinra, an IL-1α/β inhibitor, in patients with COVID-19 and high serum levels of soluble plasminogen activator receptor, according to a @NatureMedicine paper. https://t.co/aM5teLMipK pic.twitter.com/bTVNqbBOcv
— Nature Portfolio (@NaturePortfolio) September 3, 2021
Estudo mostra que as concentrações de troponina cardíaca à apresentação são insuficientes para distinguir infarto do miocárdio tipo 1 de outras causas de lesão miocárdica.
6 Set, 2021 | 16:21h
Comentário no Twitter
Cardiac troponin release kinetics: levels at presentation cannot distinguish type 1 MI from other causes of injury or infarction. Results now online @CircAHA https://t.co/8cjyl6SGai@HighSTEACS @chapdoc1 @djlmed @DorienKimenai @EdinUniCVS pic.twitter.com/v0RoD532Jx
— Ryan Wereski (@RyanWereski) June 25, 2021
Revisão | Complicações musculoesqueléticas após doença crítica.
3 Set, 2021 | 12:37h
Comentário no Twitter
Very pleased that our scoping review on MSK complications following critical illness has been published – first paper from my PhD! @mawilliamsinOx @helendawes2 @matthewjrowland @ouh_therapies @MOReS_OBU #icurehab https://t.co/f6kHDtMzrj pic.twitter.com/bOm3YvLP5U
— Owen Gustafson (@OxfordICUPhysio) August 26, 2021
Estudo randomizado | Baricitinibe reduziu a mortalidade em adultos hospitalizados com COVID-19.
3 Set, 2021 | 11:22hComentários:
Comentários no Twitter
NEW—Baricitinib did not improve the composite primary endpoint of progression to NIV,
high-flow O2, IMV, or death; however, it did reduce 28-day all-cause mortality by 38·2% vs placebo (HR 0·57 [95% CI 0·41–0·78])Read the COV-BARRIER study: https://t.co/QrU6GW0XcQ#ISICEM2021
— The Lancet Respiratory Medicine (@LancetRespirMed) September 1, 2021
(thread – click for more)
1/🧵💥 NEW COVID THERAPY SAVES LIVES
Adding baricitinib to steroids will save 1,000s of hospitalized #COVID pts. Our @LancetRespirMed COV-Barrier study is FREE.
I explain👇why it’s such a great #Pandemic discovery story: a new way to ⬇️ COVID19 deaths.https://t.co/8I5BlwyT2R pic.twitter.com/6KcfQrljqC
— WesElyMD (@WesElyMD) September 1, 2021
Diretriz científica | Covid-19 e insuficiência cardíaca.
3 Set, 2021 | 11:19h
Comentário no Twitter
Released today: Coronavirus Disease-2019 and Heart Failure: A Scientific Statement from @HFSA, published in @JCardFail. @dranulala @ankeetbhatt @EricAdler17 @BhadeliaMD @AshishCorrea @ersied727 @heartofthemater @AndrewJSauer @NMHheartdoc @scottdsolomon https://t.co/fyWab32ruU pic.twitter.com/8pNY60I6gD
— HFSA (@HFSA) September 1, 2021
Estudo randomizado | Entre pacientes criticamente doentes, a meta de oxigenação em um intervalo normal baixo vs. intervalo normal alto não resultou em redução na disfunção de órgãos.
3 Set, 2021 | 11:12hEffect of Low-Normal vs High-Normal Oxygenation Targets on Organ Dysfunction in Critically Ill Patients: A Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Conteúdos relacionados:
M-A of randomized trials: Conservative oxygen therapy for critically ill patients.
Oxygen administration for patients with ARDS – Journal of Intensive Care
Comentário no Twitter
Multicenter RCT found, among critically ill patients, targeting oxygenation to a low-normal range compared with a high-normal range did not result in a statistically significant reduction in organ dysfunction https://t.co/lEq28bqmM4 #ISICEM21
— JAMA (@JAMA_current) August 31, 2021
Estudo randomizado | Em pacientes com insuficiência respiratória hipoxêmica, uma estratégia de ventilação com volume corrente mais baixo, facilitada pela remoção extracorpórea de dióxido de carbono, não foi associada com desfechos melhores.
3 Set, 2021 | 11:10hEffect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Conteúdo relacionado: Randomized Trial: Low vs Intermediate Tidal Volume Strategy in ICU Patients Without ARDS
Comentário no Twitter
In this randomized clinical trial that included 412 adults, 90-day mortality was 41.5% in the extracorporeal carbon dioxide removal group and 39.5% in the standard care group, a difference that was not statistically significant https://t.co/jhCY2r4qjX #ISICEM21
— JAMA (@JAMA_current) August 31, 2021
Revisão | Tratamento antimicrobiano inicial na sepse – terapia imediata, empírica e de amplo espectro é fundamental, mas deve ser acompanhada por um comprometimento em de-escalonar e por gestão de antimicrobianos.
2 Set, 2021 | 11:33hInitial antimicrobial management of sepsis – Critical Care
#ESCCongress – Estudo randomizado | Vacinação precoce contra Influenza após infarto do miocárdio (IM) ou em doença coronariana de alto risco resultou em menor risco de morte por todas as causas, IM ou trombose de stent em comparação com placebo.
2 Set, 2021 | 11:13hComentários:
IAMI: Influenza Vaccine Beneficial for Post-MI Patients – TCTMD
Influenza Vaccination After Myocardial Infarction – IAMI – American College of Cardiology
Flu vaccine after heart attack reduces risk of death – Cardiovascular Business
Comentário no Twitter
The IAMI trial showed that #fluvaccine within 72 hours of angiography/PCI/hospitalization among patients with recent #cvMI or high-risk coronary heart disease resulted in a salutary effect on CV outcomes at 12 months compared w/ placebo: https://t.co/csnS3G8vsa #ESCCongress pic.twitter.com/5JB4iUmMbV
— American College of Cardiology (@ACCinTouch) August 30, 2021
Estudo de coorte | Pacientes com Covid-19 infectados pela variante Delta são 2 vezes mais suscetíveis à necessidade de admissão hospitalar ou atendimento de emergência.
30 Ago, 2021 | 13:41hComentários:
Covid: Delta variant patients twice as likely to need hospital care – BBC
Covid-19 hospitalization risk doubles with Delta variant, UK study suggests – CNN
Comentário no Twitter
The Delta variant is bad enough, but there has been debate as to whether it, per se, carries a higher risk of hospitalization (H) beyond its very high contagiousness. A new, rigorous study shows a doubling of the H rate https://t.co/qom8l6fw4v pic.twitter.com/CwXPOU0YWi
— Eric Topol (@EricTopol) August 27, 2021